MONROVIA, Calif., Aug. 11 /PRNewswire-FirstCall/ -- STAAR Surgical Company (Nasdaq: STAA), a leading developer, manufacturer and marketer of minimally invasive ophthalmic products, announced today that it will present at the at the upcoming Fourth Annual Noble Financial Equity Conference which will be held Monday, August 18th - Tuesday, August 19th, 2008 at the Loews Lake Las Vegas Resort, Nevada. Barry G. Caldwell, President and Chief Executive Officer will discuss the Company's business strategy and historical financial performance at 11:00 a.m. Pacific Time on Monday, August 18th.

ASHBURN, Va., Aug. 8 /PRNewswire/ -- Innocoll, Inc., a privately-held biopharmaceutical company, announced that the last patient has been dosed in the first of three ongoing phase 2 clinical trials sponsored by its wholly owned subsidiary, Innocoll Technologies Ltd, to investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the management of post-operative pain.

FORT WORTH, Texas, Aug. 6 /PRNewswire-FirstCall/ -- Wound Care Innovations, LLC, a subsidiary of Wound Management Technologies, Inc., (OTC Bulletin Board: WNDM), announced today that it has entered into a confidentiality agreement with a company to register and distribute their advanced wound care collagen products, CellerateRx(R), in Taiwan. "We have had a tremendous response and inquiries from the international community about CellerateRx(R)," states Cathy Bradshaw, President of Wound Care Innovations. "We are very excited about the marketing and distribution of CellerateRx(R) in Taiwan as well as the entire international community." CellerateRx(R) is FDA cleared for use on acute and chronic wounds which include but are not limited to pressure ulcers (stages I-IV), traumatic wounds, diabetic ulcers, surgical wounds, venous stasis ulcers, ulcers due to arterial insufficiency, superficial wounds, and 1st and 2nd degree burns. Its ease of application can increase patient compliance and provide minimal lifestyle interruption.

MERRIMACK, N.H., Aug. 6 /PRNewswire/ -- A premier aesthetics company focused on body shaping, Eleme Medical Inc. announced today that Grant Stevens, MD, will be the first Los Angeles based plastic surgeon to offer the SmoothShapes(R) system for longer lasting cellulite treatment.

EXTON, Pa., Aug. 5 /PRNewswire-FirstCall/ -- Isolagen(TM), Inc. (Amex: ILE) announced today positive top-line efficacy and safety results from two pivotal, Phase III clinical studies (Studies IT-R-005 and IT-R-006) of the Isolagen Therapy(TM) for the treatment of nasolabial folds, or wrinkles. Each study, conducted under an FDA Special Protocol Assessment (SPA), met all primary endpoints and was highly statistically significant, making this a major clinical milestone for the Company.

MERRIMACK, N.H., July 31 /PRNewswire/ -- A premier aesthetics company focused on body shaping, Eleme Medical Inc. announced today that Gary D. Hall, MD, will be the first Kansas City plastic surgeon to offer the SmoothShapes(R) system for longer-lasting cellulite treatment at Rajeunir Medical Spas in Leawood, Lee's Summit and Northland Kansas City. Rajeunir is hosting a SmoothShapes open house to introduce the treatments to patients and the press on Tuesday, August 5 from 6-8pm. The address is 11401 Nall Ave. Suite 218 Leawood, Kansas 66211.

MONROVIA, Calif., July 31 /PRNewswire-FirstCall/ -- STAAR Surgical Company (Nasdaq: STAA), a leading developer, manufacturer and marketer of minimally invasive ophthalmic products, today announced today that Barry G. Caldwell, President and Chief Executive Officer will present at the 2008 BMO Capital Markets Focus on Healthcare Conference at the Millennium Broadway Hotel on Tuesday, August 5th at 10:45am Eastern Time.

MONROVIA, Calif., July 31 /PRNewswire-FirstCall/ -- STAAR Surgical Company (Nasdaq: STAA), a leading developer, manufacturer and marketer of minimally invasive ophthalmic products, today announced today that Barry G. Caldwell, President and Chief Executive Officer will present at the 2008 BMO Capital Markets Focus on Healthcare Conference at the Millennium Broadway Hotel on Tuesday, August 5th at 10:45am Eastern Time.

FORT WORTH, Texas, July 30 /PRNewswire/ -- Wound Care Innovations, LLC, a subsidiary of Wound Management Technologies, Inc., (OTC Bulletin Board: WNDM), announced today an evidence based study with a NE podiatric clinic evaluating the clinical performance of their advanced wound care collagen product, CellerateRx(R), on diabetic venous ulcers. "According to data released by the Centers for Disease Control and Prevention, diabetes now affects nearly 24 million people in the United States alone," states Cathy Bradshaw, President of Wound Care Innovations. Venous stasis ulcers of the lower extremity is a common problem among diabetic patients and presents significant quality of life issues for them as well as tremendous costs to the healthcare system. It has been estimated that venous ulcers cause the loss of approximately 2 million working days and incur treatment costs of approximately $3 billion per year in the United States.(1) "We have had very positive feedback from clinicians using CellerateRx(R) on these types of wounds. We look forward to providing this data to the medical community," Bradshaw said.

MONROVIA, Calif., July 30 /PRNewswire-FirstCall/ -- STAAR Surgical Company (Nasdaq: STAA), a leading developer, manufacturer and marketer of minimally invasive ophthalmic products, today reported continued progress during its second quarter ended June 27, 2008. The financial results for the period include the operating performance of STAAR Japan, which STAAR acquired at the beginning of fiscal year 2008.